Evaluation of the LDN-0060609 PERK Inhibitor as a Selective Treatment for Primary Open-Angle Glaucoma: An In Vitro Study on Human Retinal Astrocytes
Wioletta Rozpędek‐Kamińska(Medical University of Lodz), Ireneusz Majsterek(Medical University of Lodz)
Cited by 3
Related Papers
The Potential Role of Small-Molecule PERK Inhibitor LDN-0060609 in Primary Open-Angle Glaucoma Treatment
|International Journal of Molecular Sciences|2021|14
IRE1/JNK Is the Leading UPR Pathway in 6-OHDA-Induced Degeneration of Differentiated SH-SY5Y Cells
|International Journal of Molecular Sciences|2024|9
Noradrenaline Protects Human Microglial Cells (HMC3) Against Apoptosis and DNA Damage Induced by LPS and Aβ1-42 Aggregates In Vitro
|International Journal of Molecular Sciences|2024|2
Inhibition of pro-apoptotic UPR pathways PERK/CHOP and IRE1/JNK protects differentiated SH-SY5Y cells against rotenone-induced toxicity
|Frontiers in Molecular Neuroscience|2025|0
Pharmacological Inhibition of JNK Signalling Exerts Anti-Neoplastic Effects on SH-SY5Y Human Neuroblastoma Cells
|International Journal of Molecular Sciences|2025|0